We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Product Safety Report for Irodis B.B. Clear Skin Lightening Cream presenting a serious chemical risk.
Falsified, potentially harmful Ozempic▼ and Saxenda products have been found in the UK.
This Prosperity Fund programme aims to improve health in 8 partner countries, contributing to inclusive economic growth and reducing poverty.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (27 December) approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of 12.
Product Safety Report for Super Eclaircissant White Absolute, Skin Whitening Cream presenting a serious chemical risk.
Fake, potentially harmful Ozempic and Saxenda pens have been found in the UK: you should only access these medicines via a medical prescription.
Updates from MHRA on the suspension of devices made by Silimed
Max Remedies has identified an infrequent printing error relating to the Braille text printed on the cartons of various batches of this product.
Exeltis UK Limited has informed the MHRA regarding an inconsistency in the Patient Information Leaflet (PIL) packaged in cartons of the specified batches of Gepretix 100mg capsules.
Product Recall for NassifMD Deco-Lift Neck Firming Complex Serum presenting a health risk.
Patients with a certain type of advanced or spreading non-small cell lung cancer (NSCLC) could access a new cancer therapy to help treat their condition.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).